Synageva Kicks into High Gear with its $156M Public Offering
In its fourth substantial public offering in two years, Synageva Biopharma Corp. padded its balance sheet with a $155.7 million to accelerate its aspirations of becoming a global rare disease company replete with burgeoning pipeline programs, manufacturing and commercial infrastructure.
That’s a plan investors appear to be endorsing wholeheartedly, no doubt fueled by growing enthusiasm for the rare disease space, as evidenced by rampant buyout speculation involving Alexion Pharmaceuticals Inc. and Biomarin Pharmaceutical Inc. (See BioWorld Today, Sept. 20, 2013.)
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST